The strong expression of CD166 on migrasomes (see above) and/or the presence or absence of CD166 interacting partner(s) therein or on hematopoietic cells might explain such differential impact between MSCs and their migrasome networks and between cancer cells and CD34+ HSPCs. This evidence concerns the gene CD34 and cancer.